Overview

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Status:
Terminated
Trial end date:
2019-12-19
Target enrollment:
Participant gender:
Summary
A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients with Relapsed or Refractory Lymphomas
Phase:
Phase 1
Details
Lead Sponsor:
Rhizen Pharmaceuticals SA